Información del producto
Información adicional
Storage Conditions
-20°C/1 year
Applications
ELISA
IF
IHC
IF
IHC
Concentration
1 mg/ml
Recomended Dilution
Immunohistochemistry: 1/100 - 1/300. ELISA: 1/10000. Not yet tested in other applications.
Type Clonality
Polyclonal
Immunogen
The antiserum was produced against synthesized peptide derived from human SENP6. AA range:1042-1091
Subcellular Location
Nucleus .
Iso type
IgG
Tissue Source
Rabbit
Reactivity
Human
Mouse
Rat
Mouse
Rat
Human Gen
26054
Other Name
FKSG6
KIAA0797
SENP6
SSP1
SUMO-1-specific protease 1
SUSP1
Sentrin-specific protease 6
Sentrin/SUMO-specific protease SENP6
KIAA0797
SENP6
SSP1
SUMO-1-specific protease 1
SUSP1
Sentrin-specific protease 6
Sentrin/SUMO-specific protease SENP6
Background
MIM 164008) from degradation by the 26S proteasome. Like ubiquitin, UBLs are synthesized as precursor proteins, with 1 or more amino acids following the C-terminal glycine-glycine residues of the mature UBL protein. Thus, the tail sequences of the UBL pre
MIM 601912), are structurally related to ubiquitin (MIM 191339) and can be ligated to target proteins in a similar manner as ubiquitin. However, covalent attachment of UBLs does not result in degradation of the modified proteins. SUMO1 modification is imp
Ubiquitin-like molecules (UBLs), such as SUMO1 (UBL1
MIM 601912), are structurally related to ubiquitin (MIM 191339) and can be ligated to target proteins in a similar manner as ubiquitin. However, covalent attachment of UBLs does not result in degradation of the modified proteins. SUMO1 modification is imp
Ubiquitin-like molecules (UBLs), such as SUMO1 (UBL1